Enasidenib – First-in-Class Mutant IDH2 Inhibitor Therapy
Enasidenib is an oral, first-in-class, highly selective small-molecule targeted inhibitor of the mutant isocitrate dehydrogenase 2 (IDH2) enzyme engineered for precision oncology therapy. The drug is developed for the targeted management of specific aggressive subtypes of acute myeloid leukemia (AML). The mechanism of action of enasidenib fundamentally differs from standard cytotoxic chemotherapy: it focuses on restoring normal cellular differentiation. In tumor cells harboring somatic IDH2 mutations (most commonly at codons R140 and R172), the enzyme gains an abnormal neomorphic activity, catalyzing the reduction of alpha-ketoglutarate to the oncometabolite 2-hydroxyglutarate (2-HG). Accumulation of 2-HG blocks alpha-ketoglutarate-dependent dioxygenases, inducing global hypermethylation of DNA and histones, which halts myeloid progenitor cell differentiation. Enasidenib allosterically binds to the mutant IDH2 dimer, reducing intracellular 2-HG levels by over 90%. This drives epigenetic remodeling, releases the differentiation block, and forces leukemic blasts to mature into functional, non-malignant neutrophils.
The clinical uniqueness of enasidenib lies in its capacity to achieve durable hematologic responses and remissions in patients with relapsed or refractory AML through the phenomenon of non-cytotoxic tumor clone differentiation. The drug displays high oral bioavailability, reaching steady-state plasma concentrations within approximately 21 days of continuous daily dosing. Enasidenib is characterized by an exceptionally prolonged elimination half-life (around 137 hours), is extensively metabolized in the liver via multiple cytochrome pathways (principally CYP2C19, CYP3A4, and CYP2D6) alongside direct glucuronidation, and is excreted predominantly in the feces.
The drug is administered orally. Prior to initiating treatment, documentation of the somatic IDH2 mutation status (R140 or R172) using a validated molecular-genetic diagnostic PCR or NGS assay is mandatory. Strict clinical monitoring of complete blood counts and blood biochemistry parameters is required throughout therapy.
Indications
Enasidenib is indicated as a precision targeted monotherapy for adult patients with the following malignant hematological disease:
- Relapsed or Refractory Acute Myeloid Leukemia (AML): treatment of adult patients with relapsed or refractory acute myeloid leukemia harboring a confirmed somatic mutation in the IDH2 gene (specifically at codons R140 or R172).
Dosage and administration
The dosing regimen of enasidenib is continuous and structured for long-term daily administration, with parameters for treatment interruption or step-down modification based on clinical toxicities.
- Standard Dose: the recommended initial dose is 100 mg taken orally once daily.
- Schedule and Duration: the drug is taken daily within conventional 28-day cycles. Treatment should be maintained for a minimum of 6 months to allow adequate time for a clinical response assessment, unless rapid disease progression or unacceptable systemic toxicity occurs.
- Administration Method: tablets must be swallowed whole at approximately the same time each day, with or without food. Tablets must not be broken, crushed, or chewed, and should be administered with a full glass of water.
- Missed Dose: if a dose is missed or if vomiting occurs shortly after administration, an additional capsule must not be taken that day. The patient should skip the missed dose and resume their regular schedule the following day at the planned time.
- Dose Modification: if Differentiation Syndrome, asymptomatic total bilirubin elevations greater than 3 times the upper limit of normal, or QTc interval prolongation occurs, therapy must be withheld until toxicity resolves to Grade 1-2, followed by a dose reduction to 50 mg once daily.
